

**Table. Prior COPD medication use according to therapeutic category.** The proportion of patients using pre-study medication for COPD. Pre-study medication was defined as any medication taken within 15 days prior to informed consent up to the date of informed consent (safety population).

<b>COPD medication category, n (%)<sup>a</sup></b>	<b>N=112</b>
Any COPD medication	100 (89.3)
SABA	84 (75.0)
LAMA	37 (33.0)
LABA	22 (19.6)
LABA + ICS	22 (19.6)
ICS	15 (13.4)
Other <sup>b</sup>	9 (8.0)
SABA + SAMA	6 (5.4)

<sup>a</sup>Patients were counted separately in each of the medication categories.

<sup>b</sup>COPD medications used by  $\leq 3$  patients each. Includes SAMAs, xanthines, influenza vaccines, oral PDE4 inhibitors, oxygen and systemic corticosteroids.

COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting  $\beta_2$ -agonist; LAMA, long-acting muscarinic antagonist; PDE4, phosphodiesterase-4; SABA, short-acting  $\beta_2$ -agonist; SAMA, short-acting muscarinic antagonist.